Kbi-092 ((free)) Link

By inhibiting both FLT3 and IRAK4 simultaneously, KBI-092 aims to overcome the "bypass mechanisms" cancer cells use to survive when only one pathway is blocked.

Mutations in the FLT3 gene are among the most common genetic alterations in AML. These mutations cause the FLT3 receptor to stay "on" permanently, sending constant growth and survival signals to leukemia cells. KBI-092

They provide the necessary infrastructure—including mammalian and microbial expression systems —to ensure that experimental compounds like KBI-092 meet strict GMP (Good Manufacturing Practice) standards for human testing. Description Primary Code Drug Class Small molecule antineoplastic; Dual Kinase Inhibitor Targets FLT3 and IRAK4 Primary Indication Relapsed/Refractory Acute Myeloid Leukemia (RR-AML) Administration Oral tablet, twice daily (BID) Trial Phase Phase 1 (First-in-Human) By inhibiting both FLT3 and IRAK4 simultaneously, KBI-092

Unlike traditional therapies that target a single pathway, KBI-092 is engineered for a "two-pronged" attack on leukemia cells. Its therapeutic efficacy stems from the selective inhibition of two critical proteins: HPB 092 - AdisInsight

As of late 2025, KBI-092 has moved into the active clinical testing phase:

The ongoing research into KBI-092 represents a shift toward more sophisticated, multi-targeted therapies that address the inherent complexity and adaptability of blood cancers. HPB 092 - AdisInsight